Stüve O - Search Results

1

The potential therapeutic role of statins in central nervous system autoimmune disorders.

Stüve O, Youssef S, Dunn S, Slavin AJ, Steinman L, Zamvil SS. Stüve O, et al. Cell Mol Life Sci. 2003 Nov;60(11):2483-91. doi: 10.1007/s00018-003-3146-0. Cell Mol Life Sci. 2003. PMID: 14625690 Free PMC article. Review.

2

Pathogenesis, diagnosis, and treatment of acute disseminated encephalomyelitis.

Stüve O, Zamvil SS. Stüve O, et al. Curr Opin Neurol. 1999 Aug;12(4):395-401. doi: 10.1097/00019052-199908000-00005. Curr Opin Neurol. 1999. PMID: 10555827 Review.

3

Requirement for endocytic antigen processing and influence of invariant chain and H-2M deficiencies in CNS autoimmunity.

Slavin AJ, Soos JM, Stuve O, Patarroyo JC, Weiner HL, Fontana A, Bikoff EK, Zamvil SS. Slavin AJ, et al. Among authors: stuve o. J Clin Invest. 2001 Oct;108(8):1133-9. doi: 10.1172/JCI13360. J Clin Invest. 2001. PMID: 11602620 Free PMC article.

4

Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation.

Soos JM, Krieger JI, Stüve O, King CL, Patarroyo JC, Aldape K, Wosik K, Slavin AJ, Nelson PA, Antel JP, Zamvil SS. Soos JM, et al. Among authors: stuve o. Glia. 2001 Dec;36(3):391-405. doi: 10.1002/glia.1125. Glia. 2001. PMID: 11746775

5

Single nucleotide polymorphisms in MHC2TA, the gene encoding the MHC class II transactivator (CIITA).

Patarroyo JC, Stuve O, Piskurich JF, Hauser SL, Oksenberg JR, Zamvil SS. Patarroyo JC, et al. Among authors: stuve o. Genes Immun. 2002 Feb;3(1):34-7. doi: 10.1038/sj.gene.6363808. Genes Immun. 2002. PMID: 11857059

6

Cutting edge: oral type I IFN-tau promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate.

Soos JM, Stüve O, Youssef S, Bravo M, Johnson HM, Weiner HL, Zamvil SS. Soos JM, et al. Among authors: stuve o. J Immunol. 2002 Sep 1;169(5):2231-5. doi: 10.4049/jimmunol.169.5.2231. J Immunol. 2002. PMID: 12193686

7

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.

Youssef S, Stüve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS. Youssef S, et al. Among authors: stuve o. Nature. 2002 Nov 7;420(6911):78-84. doi: 10.1038/nature01158. Nature. 2002. PMID: 12422218

8

The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease.

Stüve O, Youssef S, Slavin AJ, King CL, Patarroyo JC, Hirschberg DL, Brickey WJ, Soos JM, Piskurich JF, Chapman HA, Zamvil SS. Stüve O, et al. J Immunol. 2002 Dec 15;169(12):6720-32. doi: 10.4049/jimmunol.169.12.6720. J Immunol. 2002. PMID: 12471103

9

Approved and future pharmacotherapy for multiple sclerosis.

Stüve O, Cree BC, von Büdingen HC, Yousef S, Bowen JD, Genain CP, Hauser SL, Steinman L, Zamvil SS. Stüve O, et al. Neurologist. 2002 Sep;8(5):290-301. doi: 10.1097/00127893-200209000-00002. Neurologist. 2002. PMID: 12803676

10

Statins as potential therapeutic agents in neuroinflammatory disorders.

Stüve O, Youssef S, Steinman L, Zamvil SS. Stüve O, et al. Curr Opin Neurol. 2003 Jun;16(3):393-401. doi: 10.1097/01.wco.0000073942.19076.d1. Curr Opin Neurol. 2003. PMID: 12858078 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

315 results

Search Page

Filters